NCT03805581View on ClinicalTrials.gov

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 12, 2018

Primary Completion Date

July 1, 2022

Study Completion Date

November 7, 2023

Conditions
Sickle Cell DiseaseAcute Chest Syndrome
Interventions
DRUG

Defibrotide

Defibrotide 6.25 mg/kg IV q6h up to 7 days

Trial Locations (1)

10595

New York Medical College, Valhalla

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

New York Medical College

OTHER